Are Investors Undervaluing Amphastar Pharmaceuticals (AMPH) Right Now?

Core Insights - Amphastar Pharmaceuticals (AMPH) is currently rated as a Zacks Rank 2 (Buy) and has a Value grade of A, indicating strong potential for value investors [2] - The PEG ratio for AMPH is 0.79, which is lower than the industry average of 1.09, suggesting that the stock may be undervalued relative to its expected earnings growth [2] - AMPH's P/B ratio stands at 3.40, which is attractive compared to the industry average of 3.98, indicating a favorable valuation based on book value [2] - The P/CF ratio for AMPH is 11.24, significantly lower than the industry average of 28.71, further supporting the notion that AMPH is undervalued based on its cash flow outlook [3] Valuation Metrics - PEG Ratio: AMPH's PEG ratio is 0.79, with a 52-week range of 0.53 to 0.97 and a median of 0.74 [2] - P/B Ratio: AMPH's P/B ratio is 3.40, with a 52-week range of 2.54 to 5.10 and a median of 3.28 [2] - P/CF Ratio: AMPH's P/CF ratio is 11.24, with a 12-month range of 8.34 to 19.33 and a median of 10.95 [3]